Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 19/20 | 1.00 |
| ▸ | CYBB | P04839 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614947 | 0.88 | NOX4 (0.84) | NOX4CYBB | |
| SCHEMBL3612480 | 0.82 | NOX4 (0.70) | NOX4CYBBKDM4EMEN1NPC1 | |
| SCHEMBL14950445 | 0.82 | NOX4 (0.83) | NOX4CYBB | |
| SCHEMBL3611341 | 0.80 | KDM4E (0.83) | NOX4CYBBKDM4EMEN1NPC1 | |
| SCHEMBL3602788 | 0.80 | NOX4 (1.00) | NOX4CYBB | |
| SCHEMBL12107188 | 0.80 | NOX4 (0.72) | NOX4CYBBMEN1MAPTKMT2A | |
| SCHEMBL3618372 | 0.80 | NOX4 (1.00) | NOX4CYBB | |
| SCHEMBL3617185 | 0.79 | NOX4 (0.65) | NOX4CYBBKDM4EMEN1NPC1 | |
| SCHEMBL3618610 | 0.78 | NOX4 (0.77) | NOX4CYBBKDM4EMEN1NPC1 | |
| SCHEMBL19956763 | 0.78 | NOX4 (0.75) | NOX4CYBBKDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | claimed |
| EP-2545918-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-08-06 | — | — | EP | claimed |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2013-05-16 | — | — | US | claimed |
| US-8389518-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-03-05 | — | — | US | claimed |
| EP-2545918-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-01-16 | — | — | EP | claimed |
| EP-2139477-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2012-12-12 | — | — | EP | claimed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | claimed |
| EP-2002835-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyo Tex (CH) | 2008-12-17 | — | — | EP | claimed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| EP-2545918-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2013-05-16 | — | — | US | disclosed |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2013-05-16 | — | — | US | disclosed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2139477-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-2002835-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyo Tex (CH) | 2008-12-17 | — | — | EP | disclosed |
| EP-2002835-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyo Tex (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008113856-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113856-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885KDM4E 3416/4885 |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885KDM4E 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.